News & Videos - Page 2

EQS-News: SURTECO GROUP SE / Schlagwort(e): Jahresbericht SURTECO GROUP SE: Guter Start in das Geschäftsjahr 2024 nach schwierigem Jahr 2023 24.04.2024 / 07:05 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. SURTECO GROUP SE: Guter Start in das Geschäftsjahr 2024 nach schwierigem Jahr 2023 Gewinn je Aktie liegt in 2023 bei -0,79 € nach 1,63 € im Vorjahr Umsatz 2024 soll bei 860 bis 910 Mio. € liegen. EBITDA adjusted wird zwischen 85 und 105 Mio. €...

Kuros Biosciences AG / Key word(s): Quarter Results/Regulatory Approval Kuros reports Corporate Highlights as of Q1 2024 including increase in direct MagnetOsTM sales 24-Apr-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Financial Highlights Direct MagnetOs sales rose by 155% to CHF 13.9 million in Q1 2024 from CHF 5.4 million in Q1 2023; this corresponds to a sequential increase of 21.9% or...

u-blox AG / Key word(s): Quarter Results u-blox reports its first quarter 2024 trading update 24-Apr-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Revenue of CHF 56.0 million Similar revenue decline in all regions and markets; decline stronger in the connectivity business EBIT of CHF -20.4 million, EBIT (adjusted) of CHF -18.6 million Q1 2024 expected to be the trough Thalwil, Switzerland –...

EQS-News: Evotec SE / Key word(s): Annual Results Evotec presents fiscal year 2023 results and announces priority reset to focus on profitable growth 24.04.2024 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. FINANCIAL RESULTS FOR 2023 FULLY MET UPDATED GUIDANCE PRIORITY RESET TO PROFITABLE GROWTH: SIZE & FOOTPRINT ADJUSTMENTS TO DRIVE EXPECTED ANNUALISED EBITDA IMPROVEMENT GREATER THAN € 40 M EVOTEC’S REPORTING STRUCTURE WILL CHANGE TO BUSINESS...

EQS-News: Evotec SE / Schlagwort(e): Jahresergebnis Evotec SE stellt Ergebnisse für das Geschäftsjahr 2023 vor und richtet Priorität auf profitables Wachstum aus 24.04.2024 / 07:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. FINANZERGEBNIS 2023 ERREICHT IN ALLEN PUNKTEN DIE AKTUALISIERTE PROGNOSE NEUAUSRICHTUNG DER PRIORITÄT AUF PROFITABLES WACHSTUM: ANPASSUNGEN BEI GRÖẞE UND STANDORTEN, UM JÄHRLICHEN EBITDA-BEITRAG VON MEHR ALS 40 MIO. € ZU...

PARIS, FRANCE, 24 avril 2024 - Ipsen (Euronext : IPN ; ADR : IPSEY), groupe biopharmaceutique mondial de spécialité, publie aujourd’hui son chiffre d’affaires pour le premier trimestre 2024. Q1 2024 Q1 2023 % change €m €m Réalisé TTC 1 Plateforme de croissance 2 509,7 452,0 12,8% 16,2% Nouveaux médicaments 3 45,5 14,3 n/a n/a Somatuline ® 257,8 263,2 -2,0% -1,3% Autres 9,5 12,4 -23,8% -20,5% Chiffre d’affaires Groupe 822,4 741,9 10.9% 13.3% Faits marquants Croissance des ventes...

Recognition given for achievement in commercializing Joenja® (leniolisib), a first-in-class medication brought to market 10 years after disease state, APDS, was first characterized Leiden, the Netherlands, April 24, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is pleased to announce its recognition as an Industry Innovator by the National Organization for Rare Disorders (NORD®) at the Rare Impact Awards on June 8, 2024. The Rare...

PRESS RELEASE - PRIVILEGED INFORMATION In view of the restructuring plan announced on April 11, 2024, BioSenic has decided to postpone the publication of its 2023 annual report as well as its annual general meeting of shareholders, so that the Enterprise Court of Nivelles can make a decision before the completion of the annual formalities. The Company believes that this postponement is preferable to ensure that the financial statements can be prepared on a going concern basis....

La Hulpe, Belgium – 24 April 2024, 7:00 a.m. CET – Unifiedpost Group SA (Euronext Brussels: UPG) (“Unifiedpost”), a leader in cloud-based business process solutions, will present an overview of its mid-term strategy on Tuesday, 30 April 2024. The event will take place from 2:00pm to 4:00pm CET on Tuesday, 30 April 2024. The presenting team will be Hans Leybaert, CEO, Koen De Brabander, CFO, and some of the group’s business leaders. The agenda for the day is as follows: Introductions...

OSLO, Norway (24 April 2024) - TGS will release its Q1 2024 results at approximately 07:00 CEST on 8 May 2024. CEO Kristian Johansen and CFO Sven Børre Larsen will present the results at 09:00 CEST at House of Oslo, Ruseløkkveien 34, Oslo, Norway. The presentation is open to the public and can be followed live online. Access and registration for online attendees are available by copying and pasting this link into your browser: https://channel.royalcast.com/landingpage/hegnarmedia/20240508_16/...

Hydro’s adjusted EBITDA for the first quarter of 2024 was NOK 5,411 million, down from NOK 7,525 million for the same quarter last year. Lower aluminium sales prices, Extrusions volumes and recycling margins, and higher fixed costs negatively impacted results, partly offset by lower raw material costs. This resulted in an adjusted RoaCE of 5.6 percent over the last twelve months. Results down on weaker demand and recycling margins, revenue drivers increasing Increasing recycling and...

The Netherlands, 24 April 2024 Vopak reports strong Q1 2024 results and increases FY 2024 outlook Key highlights Q1 2024 Improve Increased net profit -including exceptional items 1 - in Q1 2024 to EUR 106 million, an improvement of 3% year-on-year, driven by favorable storage demand across different geographies and markets Increased proportional EBITDA -excluding exceptional items 1 - in Q1 2024 to EUR 298 million, an improvement of 9% year-on-year when adjusted for divestment impacts of EUR 21...

Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates In-depth analysis of VIVIAD Phase 2b results is ongoing, including pre-specified and exploratory endpoints; findings to date are consistent with previously announced topline data observing no statistically significant or clinically meaningful effect of varoglutamstat on cognition and function in early AD up to 600mg twice a day (BID) dose Statistically significant improvement in...

By joining forces with industry leaders in the Arm Total Design ecosystem, Kalray is helping more companies integrate its AI and data-processing solution into their next-generation chips. Grenoble, France April 24, 2024 – Kalray (Euronext Growth Paris: ALKAL), a leading provider of hardware and software solutions to accelerate data intensive workflows from Cloud to Edge, announced that it has extended its collaboration with Arm by joining Arm Total Design. Through a deeper connection to...

WithSecure Corporation, Interim report release 1 January – 31 March 2024, 24 April 2024 at 8.00 EEST WithSecure Interim report 1 January – 31 March 2024: Elements Company profitability developing positively, despite slow start of the year Highlights of January – March 2024 (“first quarter”) Annual Recurring Revenue (ARR) (1) for Elements Cloud (2) increased by 10% to EUR 80.5 million (EUR 73.4 million) Elements Cloud ARR increase from previous quarter was 3% Net Revenue Retention for...

En devenant membre du programme « Arm Total Design » auprès d'autres grands leaders de l'industrie, Kalray va pouvoir aider plus de sociétés à intégrer sa solution de traitement de données et d'IA dans leurs nouvelles générations de produits. Grenoble, le 24 avril 2024 – Kalray (Euronext Growth Paris : ALKAL), leader dans les technologies matérielles et logicielles dédiées à la gestion et au traitement intensif des données du Cloud au Edge, annonce devenir membre du programme...

Bon début d’année 2024 _ COMMUNIQUÉ DE PRESSE _ Chiffre d’affaires standard de 1 692 millions d’euros au premier trimestre 2024, en croissance organique de +2,8 % par rapport à la même période de 2023 et de +4,7 % hors Autres activités Croissance organique de +6,7 % des activités d'Electrification, reflétant une croissance à deux chiffres de l’activité Production d’énergie & Transmission et une accélération globale des tendances dans l'électrification Carnet de commandes...

Borregaard’s operating revenues reached NOK 1,975 million (NOK 1,850 million) 2 in the 1 st quarter of 2024. EBITDA 1 increased to NOK 442 million (NOK 435 million). The result in BioSolutions increased while results in BioMaterials and Fine Chemicals were lower compared with the 1 st quarter of 2023. The result in BioSolutions increased due to higher sales volume and reduced energy costs. In BioMaterials, higher sales volume was more than offset by lower sales prices and higher wood costs....

PR Newswire - Start of Day PR Newswire LONDON, United Kingdom, April 24 PR Newswire This is the START of day message for the PR Newswire Disclose service =============================================================================== Disclaimer =============================================================================== The content and accuracy of all information published on the Disclose service is the responsibility of the originating company or organisation and not PR Newswire or...

Gereglementeerde informatie Tussentijdse verklaring, opgesteld door de Raad van Bestuur Ieper, België - 24 april 2024, 07.00 uur CET Geachte, hieronder vindt u de link naar ons meest recente persbericht: www.melexis.com/nl/news/2024/financial/melexis-q1-2024-results Bijlage PR_NL_Melexis_Q1 2024...